


The ORGANIC CHEMISTRY of DRUG DESIGN and DRUG ACTION

Second Edition



Richard B. Silverman

R96

W1:

The Organic Chemistry of Drug Design and Drug Action

Second Edition

Richard B. Silverman
Northwestern University
Department of Chemistry
Evanston, Illinois

江苏工业学院图书馆
藏书章



ELSEVIER
ACADEMIC
PRESS

Amsterdam • Boston • Heidelberg • London • New York • Oxford
Paris • San Diego • San Francisco • Singapore • Sydney • Tokyo

Senior Publishing Editor Jeremy Hayhurst
Project Manager Simon Crump
Editorial Assistant Desiree Marr
Marketing Manager Linda Beattie
Cover Design Eric DeCicco
Composition Newgen Imaging Systems (P) Ltd
Printer Maple-Vail Book Manufacturing Group

Elsevier Academic Press
200 Wheeler Road, Burlington, MA 01803, USA
525 B Street, Suite 1900, San Diego, California 92101-4495, USA
84 Theobald's Road, London WC1X 8RR, UK

This book is printed on acid-free paper. (∞)

Copyright © 2004, Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

Permissions may be sought directly from Elsevier's Science & Technology Rights
Department in Oxford, UK: phone: (+44) 1865 843830,
fax: (+44) 1865 853333, e-mail: permissions@elsevier.com.uk.
You may also complete your request on-line via the Elsevier homepage (<http://elsevier.com>), by selecting "Customer Support" and then "Obtaining Permissions."

Library of Congress Cataloging-in-Publication Data

Application submitted

British Library Cataloguing in Publication Data

A catalogue record for this book is available from the British Library

ISBN: 0-12-643732-7

For all information on all Academic Press publications
visit our Web site at www.academicpressbooks.com


Printed in the United States of America

03 04 05 06 07 08 9 8 7 6 5 4 3 2 1

The Organic Chemistry of Drug Design and Drug Action

Second Edition

To Mom and the memory of Dad, for their love, their humor, their ethics, their inspiration,
but also for their genes





Preface to the First Edition

From 1985 to 1989 I taught a one-semester course in medicinal chemistry to senior undergraduates and first-year graduate students majoring in chemistry or biochemistry. Unlike standard medicinal chemistry courses that are generally organized by classes of drugs, giving descriptions of their biological and pharmacological effects, I thought there was a need to teach a course based on the organic chemical aspects of medicinal chemistry. It was apparent then, and still is the case now, that there is no text that concentrates exclusively on the organic chemistry of drug design, drug development, and drug action. This book has evolved to fill that important gap. Consequently, if the reader is interested in learning about a specific class of drugs, its biochemistry, pharmacology, and physiology, he or she is advised to look elsewhere for that information. Organic chemical principles and reactions vital to drug design and drug action are the emphasis of this text with the use of clinically important drugs as examples. Usually only one or just a few representative examples of drugs that exemplify the particular principle are given; no attempt has been made to be comprehensive in any area. When more than one example is given, it generally is to demonstrate different chemistry. It is assumed that the reader has taken a one-year course in organic chemistry that included amino acids, proteins, and carbohydrates and is familiar with organic structures and basic organic reaction mechanisms. Only the chemistry and biochemistry background information pertinent to the understanding of the material in this text is discussed. Related, but irrelevant, background topics are briefly discussed or are referenced in the general readings section at the end of each chapter. Depending on the degree of in-depthness that is desired, this text could be used for a one-semester or a full-year course. The references cited can be ignored in a shorter course or can be assigned for more detailed discussion in an intense or full-year course. Also, not all sections need to be covered, particularly when multiple examples of a particular principle are described. The instructor can select those examples that may be of most interest to the class. It was the intent in writing this book that the reader, whether a student or a scientist interested in entering the field of medicinal chemistry, would learn to take a rational physical organic chemical approach to drug design and drug development and to appreciate the chemistry of drug action. This knowledge is of utmost importance for the understanding of how drugs function at the molecular level. The principles are the same regardless of the particular receptor or enzyme involved. Once the fundamentals of drug design and drug action are understood, these concepts can be applied to the understanding of the many classes of drugs that are described in classical medicinal chemistry texts. This basic understanding can be the foundation for the future elucidation of drug action or the rational discovery of new drugs that utilize organic chemical phenomena.

*Richard B. Silverman
Evanston, Illinois
April 1991*



Preface to the Second Edition

In the 12 years since the first edition was written, certain new approaches in medicinal chemistry have appeared or have become commonly utilized. The basic philosophy of this textbook has not changed, that is, to emphasize general principles of drug design and drug action from an organic chemical perspective rather than from the perspective of specific classes of drugs. Several new sections were added (in addition to numerous new approaches, methodologies, and updates of examples and references), especially in the areas of lead discovery and modification (Chapter 2). New screening approaches, including high-throughput screening, are discussed as are the concepts of privileged structures and drug-likeness. Combinatorial chemistry, which was in its infancy during the writing of the first edition, evolved, became a separate branch of medicinal chemistry, then started to wane in importance during the 21st century. Combinatorial chemistry groups, prevalent in almost all pharmaceutical industry at the end of the 20th century, began to be dissolved, and a gradual return to traditional medicinal chemistry has been seen. Nonetheless, combinatorial chemistry journals have sprung up to serve as the conduit for dissemination of new approaches in this area, and this along with parallel synthesis are important approaches that have been added to this edition. New sections on SAR by NMR and SAR by MS have also been added. Peptidomimetic approaches are discussed in detail. The principles of structure modification to increase oral bioavailability and effects on pharmacokinetics are presented, including log *P* software and “rule of five” and related ideas in drug discovery. The fundamentals of molecular modeling and 3D-QSAR also are expanded. The concepts of inverse agonism, inverse antagonism, racemic switches, and the two-state model of receptor activation are introduced in Chapter 3. In Chapter 5 efflux pumps, COX-2 inhibitors, and dual-acting drugs are discussed; a case history of the discovery of the AIDS drug ritonavir is used to exemplify the concepts of drug discovery of reversible enzyme inhibitors. Discussions of DNA structure and function, topoisomerases, and additional examples of DNA-interactive agents, including metabolically activated agents, are new or revised sections in Chapter 6. The newer emphasis on the use of HPLC/MS/MS in drug metabolism is discussed in Chapter 7 along with the concepts of fatty acid and cholesterol conjugation and antedugs. In Chapter 8 a section on enzyme-prodrug therapies (ADEPT, GDEPT, VDEPT) has been added as well as a case history of the discovery of omeprazole. Other changes include the use of both generic names and trade names, with generic names given with their chemical structure, and the inclusion of problem sets and solutions for each chapter.

The first edition of this text was written primarily for upperclass undergraduate and first-year graduate students interested in the general field of drug design and drug action. During the last decade it has become quite evident that there is a large population, particularly of synthetic organic chemists, who enter the pharmaceutical industry with little or no knowledge of medicinal chemistry and who want to learn the application of their skills to the

process of drug discovery. The first edition of this text provided an introduction to the field for both students and practitioners, but the latter group has more specific interests in how to accelerate the drug discovery process. For the student readers, the basic principles described in the second edition are sufficient for the purpose of teaching the general process of how drugs are discovered and how they function. Among the basic principles, however, I have now interspersed many more specifics that go beyond the basics and may be more directly related to procedures and applications useful to those in the pharmaceutical industry. For example, in Chapter 2 it is stated that "Ajay and coworkers proposed that *drug-likeness* is a possible inherent property of some molecules,¹ and this property could determine which molecules should be selected for screening." The basic principle is that some molecules seem to have scaffolds found in many drugs and should be initially selected for testing. But following that initial statement is added more specifics: "They used a set of one- and two-dimensional parameters in their computation and were able to predict correctly over 90% of the compounds in the Comprehensive Medicinal Chemistry (CMC) database.² Another computational approach to differentiate drug-like and nondrug-like molecules using a scoring scheme was developed,³ which was able to classify correctly 83% of the compounds in the Available Chemicals Directory (ACD)⁴ and 77% of the compounds in the World Drug Index (WDI).⁵ A variety of other approaches have been taken to identify drug-like molecules."⁶ I believe that the student readership does not need to clutter its collective brain with these latter specifics, but should understand the basic principles and approaches; however, for those who aspire to become part of the pharmaceutical research field, they might want to be aware of these specifics and possibly look up the references that are cited (the instructor for a course who believes certain specifics are important may assign the references as readings).

For concepts peripheral to drug design and drug action, I will give only a reference to a review of that topic in case the reader wants to learn more about it. If the instructor believes that a particular concept that is not discussed in detail should have more exposure to the class, further reading can be assigned.

To minimize errors in reference numbers, several references are cited more than once under different endnote numbers. Also, although multiple ideas may come from a single reference, the reference is only cited once; if you want to know the origin of discussions in the text, look in the closest reference, either the one preceding the discussion or just following it. Because my expertise extends only in the areas related to enzymes and the design of enzyme inhibitors,

¹ Ajay; Walters, W. P.; Murcko, M. A. *J. Med. Chem.* **1998**, *41*, 3314.

² This is an electronic database of Volume 6 of *Comprehensive Medicinal Chemistry* (Pergamon Press) available from MDL Information systems, Inc., San Leandro, CA 94577.

³ Sadowski, J.; Kubinyi, H. *J. Med. Chem.* **1998**, *41*, 3325.

⁴ The ACD is available from MDL Information systems, Inc., San Leandro, CA, and contains specialty and bulk commercially available chemicals.

⁵ The WDI is from Derwent Information.

⁶ (a) Walters, W. P.; Stahl, M. T.; Murcko, M. A. *Drug Discovery Today* **1998**, *3*, 160. (b) Walters, W. P.; Ajay; Murcko, M. A. *Curr. Opin. Chem. Biol.* **1999**, *3*, 384. (c) Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. *Angew. Chem. Int. Ed. Engl.* **1999**, *38*, 3743. (d) Oprea, T. I. *J. Comput.-Aided Mol. Des.* **2000**, *14*, 251. (e) Gillet, V. J.; Willett, P. L.; Bradshaw, J. J. *Chem. Inf. Comput. Sci.* **1998**, *38*, 165. (f) Wagener, M.; vanGeerestein, V. J. *J. Chem. Inf. Comput. Sci.* **2000**, *40*, 280. (g) Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J. *J. Comb. Chem.* **1999**, *1*, 55. (h) Xu, J.; Stevenson, J. J. *Chem. Inf. Comput. Sci.* **2000**, *40*, 1177. (i) Muegge, I.; Heald, S. L.; Brittelli, D. *J. Med. Chem.* **2001**, *44*, 1841. (j) Anzali, S.; Barnickel, G.; Cezanne, B.; Krug, M.; Filimonov, D.; Poroikov, V. *J. Med. Chem.* **2001**, *44*, 2432. (k) Brstle, M.; Beck, B.; Schindler, T.; King, W.; Mitchell, T.; Clark, T. *J. Med. Chem.* **2002**, *45*, 3345.

I want to thank numerous experts who read parts or whole chapters and gave me feedback for modification. These include (in alphabetical order) Shuet-Hing Lee Chiu, Young-Tae Chang, William A. Denny, Perry A. Frey, Richard Friary, Kent S. Gates, Laurence H. Hurley, Haitao Ji, Theodore R. Johnson, Yvonne C. Martin, Ashim K. Mitra, Shahriar Mobashery, Sidney D. Nelson, Daniel H. Rich, Philippa Solomon, Richard Wolfenden, and Jian Yu. Your input is greatly appreciated.

*Richard B. Silverman
still in Evanston, Illinois
May 2003*

Contents

Preface to the First Edition	xv
Preface to the Second Edition	xvii
1 Introduction	1
1.1 Medicinal Chemistry Folklore	1
1.2 Discovery of New Drugs	2
1.3 General References	3
1.4 References	4
2 Drug Discovery, Design, and Development	7
2.1 Drug Discovery	8
2.1.A Drug Discovery without a Lead	9
A.1 Penicillins	9
A.2 Librium	10
2.1.B Lead Discovery	11
B.1 Random Screening	13
B.2 Nonrandom (or Targeted or Focused) Screening	14
B.3 Drug Metabolism Studies	14
B.4 Clinical Observations	15
B.5 Rational Approaches to Lead Discovery	16
2.2 Lead Modification: Drug Design and Development	17
2.2.A Identification of the Active Part: The Pharmacophore	17
2.2.B Functional Group Modification	21
2.2.C Structure–Activity Relationships	21
2.2.D Privileged Structures and Drug-Like Molecules	24
2.2.E Structure Modifications to Increase Potency and the Therapeutic Index	25
E.1 Homologation	26
E.2 Chain Branching	26
E.3 Ring-Chain Transformations	28
E.4 Bioisosterism	29
E.5 Combinatorial Chemistry	34
a. General Aspects	34
b. Split Synthesis: Peptide Libraries	36

c. Encoding Combinatorial Libraries	38
d. Nonpeptide Libraries	41
E.6 SAR by NMR/SAR by MS	44
E.7 Peptidomimetics	47
2.2.F Structure Modifications to Increase Oral Bioavailability	51
F.1 Electronic Effects: The Hammett Equation	51
F.2 Lipophilicity Effects	53
a. Importance of Lipophilicity	53
b. Measurement of Lipophilicities	55
c. Computerization of Log <i>P</i> Values	61
d. Membrane Lipophilicity	62
F.3 Effects of Ionization on Lipophilicity and Oral Bioavailability . . .	62
F.4 Other Properties that Influence Oral Bioavailability and Ability to Cross the Blood–Brain Barrier	65
2.2.G Quantitative Structure–Activity Relationships	66
G.1 Historical	66
G.2 Steric Effects: The Taft Equation and Other Equations	67
G.3 Methods Used to Correlate Physicochemical Parameters with Biological Activity	68
a. Hansch Analysis: A Linear Multiple Regression Analysis . . .	68
b. Free and Wilson or <i>de novo</i> Method	70
c. Enhancement Factor	71
d. Manual Stepwise Methods: Topliss Operational Schemes and Others	71
e. Batch Selection Methods: Batchwise Topliss Operational Scheme, Cluster Analysis, and Others	73
G.4 Computer-Based Methods of QSAR Related to Receptor Binding: 3D-QSAR	75
2.2.H Molecular Graphics-Based Drug Design	78
2.2.I Epilogue	86
2.3 General References	87
2.4 Problems	100
2.5 References	105
3 Receptors	121
3.1 Introduction	122
3.2 Drug–Receptor Interactions	123
3.2.A General Considerations	123
3.2.B Interactions (Forces) Involved in the Drug–Receptor Complex	124
B.1 Covalent Bonds	125
B.2 Ionic (or Electrostatic) Interactions	125
B.3 Ion–Dipole and Dipole–Dipole Interactions	125
B.4 Hydrogen Bonds	125
B.5 Charge-Transfer Complexes	127
B.6 Hydrophobic Interactions	129

B.7	Van der Waals or London Dispersion Forces	129
B.8	Conclusion	130
3.2.C	Determination of Drug–Receptor Interactions	131
3.2.D	Theories for Drug–Receptor Interactions	137
D.1	Occupancy Theory	137
D.2	Rate Theory	139
D.3	Induced-Fit Theory	139
D.4	Macromolecular Perturbation Theory	139
D.5	Activation-Aggregation Theory	140
D.6	The Two-State (Multistate) Model of Receptor Activation	141
3.2.E	Topographical and Stereochemical Considerations	142
E.1	Spatial Arrangement of Atoms	142
E.2	Drug and Receptor Chirality	143
E.3	Geometric Isomers (Diastereomers)	151
E.4	Conformational Isomers	152
E.5	Ring Topology	158
3.2.F	Ion Channel Blockers	158
3.2.G	Case History of Rational Drug Design of a Receptor Antagonist: Cimetidine	159
3.3	General References	165
3.4	Problems	166
3.5	References	168
4	Enzymes	173
4.1	Enzymes as Catalysts	174
4.1.A	What Are Enzymes?	174
4.1.B	How Do Enzymes Work?	174
B.1	Specificity of Enzyme-Catalyzed Reactions	176
a.	Binding Specificity	176
b.	Reaction Specificity	177
B.2	Rate Acceleration	178
4.2	Mechanisms of Enzyme Catalysis	179
4.2.A	Approximation	179
4.2.B	Covalent Catalysis	181
4.2.C	General Acid–Base Catalysis	182
4.2.D	Electrostatic Catalysis	184
4.2.E	Desolvation	185
4.2.F	Strain or Distortion	185
4.2.G	Example of the Mechanisms of Enzyme Catalysis	186
4.3	Coenzyme Catalysis	188
4.3.A	Pyridoxal 5'-Phosphate (PLP)	188
A.1	Racemases	194
A.2	Decarboxylases	195
A.3	Aminotransferases (Formerly Transaminases)	195
A.4	PLP-Dependent β -Elimination	200
4.3.B	Tetrahydrofolate and Pyridine Nucleotides	200
4.3.C	Flavin	205

C.1	Two-Electron (Carbanion) Mechanism	209
C.2	Carbanion Followed by Two One-Electron Transfers	209
C.3	One-Electron Mechanism	210
C.4	Hydride Mechanism	210
4.3.D	Heme	212
4.3.E	Adenosine Triphosphate and Coenzyme A	214
4.4	Enzyme Therapy	216
4.5	General References	217
4.6	Problems	218
4.7	References	222
5	Enzyme Inhibition and Inactivation	227
5.1	Why Inhibit an Enzyme?	229
5.2	Drug Resistance	231
5.2.A	What Is Drug Resistance?	231
5.2.B	Mechanisms of Drug Resistance	232
B.1	Altered Drug Uptake	232
B.2	Overproduction of the Target Enzyme	232
B.3	Altered Target Enzyme (or Site of Action)	232
B.4	Production of a Drug-Destroying Enzyme	235
B.5	Deletion of a Prodrug-Activating Enzyme	238
B.6	Overproduction of the Substrate for the Target Enzyme	239
B.7	New Pathway for Formation of the Product of the Target Enzyme	239
B.8	Efflux Pumps	239
5.3	Drug Synergism (Drug Combination)	239
5.3.A	What Is Drug Synergism?	239
5.3.B	Mechanisms of Drug Synergism	239
B.1	Inhibition of a Drug-Destroying Enzyme	239
B.2	Sequential Blocking	240
B.3	Inhibition of Enzymes in Different Metabolic Pathways	240
B.4	Efflux Pump Inhibitors	240
B.5	Use of Multiple Drugs for the Same Target	240
5.4	Reversible Enzyme Inhibitors	241
5.4.A	Mechanism of Reversible Inhibition	241
5.4.B	Selected Examples of Competitive Reversible Inhibitor Drugs	242
B.1	Simple Competitive Inhibition: Captopril, Enalapril, Lisinopril, and Other Antihypertensive Drugs	242
a.	Humoral Mechanism for Hypertension	243
b.	Lead Discovery	243
c.	Lead Modification and Mechanism of Action	244
d.	Dual-Acting Drugs: Dual-Acting Enzyme Inhibitors	250
B.2	Alternative Substrate Inhibition: Sulfonamide Antibacterial Agents (Sulfa Drugs)	254
a.	Lead Discovery	254
b.	Lead Modification	255
c.	Mechanism of Action	255
d.	Drug Resistance	257
e.	Drug Synergism	257

5.4.C	Transition State Analogs and Multisubstrate Analogs	258
C.1	Theoretical Basis	258
C.2	Transition State Analogs	259
a.	Enalaprilat	259
b.	Pentostatin	259
c.	Multisubstrate Analogs	262
5.4.D	Slow, Tight-Binding Inhibitors	262
D.1	Theoretical Basis	262
D.2	Enalaprilat	263
D.3	Lovastatin and Simvastatin, Antihypercholesterolemic Drugs	263
a.	Cholesterol and Its Effects	263
b.	Lead Discovery	263
c.	Mechanism of Action	264
d.	Lead Modification	265
D.4	Peptidyl Trifluoromethyl Ketone Inhibitors of Human Leukocyte Elastase	267
5.4.E	Case History of Rational Drug Design of an Enzyme Inhibitor: Ritonavir	268
E.1	Lead Discovery	268
E.2	Lead Modification	269
5.5	Irreversible Enzyme Inhibitors	274
5.5.A	Potential of Irreversible Inhibition	274
5.5.B	Affinity Labeling Agents	275
B.1	Mechanism of Action	275
B.2	Selected Affinity Labeling Agents	277
a.	Penicillins and Cephalosporins/Cephameycins	277
b.	Aspirin	280
5.5.C	Mechanism-Based Enzyme Inactivators	285
C.1	Theoretical Aspects	285
C.2	Potential Advantages in Drug Design Relative to Affinity Labeling Agents	286
C.3	Selected Examples of Mechanism-Based Enzyme Inactivators	287
a.	Vigabatrin, an Anticonvulsant Drug	287
b.	Eflornithine, an Antiprotozoal Drug and Beyond	290
c.	Tranylcypromine, an Antidepressant Drug	292
d.	Selegiline (<i>L</i> -Deprenyl), an Antiparkinsonian Drug	295
e.	5-Fluoro-2'-Deoxyuridylate, Floxuridine, and 5-Fluorouracil, Antitumor Drugs	298
5.6	General References	302
5.7	Problems	303
5.8	References	307
6	DNA-Interactive Agents	323
6.1	Introduction	324
6.1.A	Basis for DNA-Interactive Drugs	324
6.1.B	Toxicity of DNA-Interactive Drugs	325
6.1.C	Combination Chemotherapy	327

6.1.D	Drug Interactions	327
6.1.E	Drug Resistance	327
6.2	DNA Structure and Properties	328
6.2.A	Basis for the Structure of DNA	328
6.2.B	Base Tautomerization	332
6.2.C	DNA Shapes	334
6.2.D	DNA Conformations	341
6.3	Classes of Drugs That Interact with DNA	342
6.3.A	Reversible DNA Binders	344
A.1	External Electrostatic Binding	345
A.2	Groove Binding	345
A.3	Intercalation and Topoisomerase-Induced DNA Damage	346
a.	Amsacrine, an Acridine Analog	349
b.	Dactinomycin, the Parent Actinomycin Analog	350
c.	Doxorubicin (Adriamycin) and Daunorubicin (Daunomycin), Anthracycline Antitumor Antibiotics	351
d.	Bisintercalating Agents	352
6.3.B	DNA Alkylators	353
B.1	Nitrogen Mustards	354
a.	Lead Discovery	354
b.	Chemistry of Alkylating Agents	354
c.	Lead Modification	356
d.	Drug Resistance	358
B.2	Ethylenimines	358
B.3	Methanesulfonates	358
B.4	(+)-CC-1065 and Duocarmycins	359
B.5	Metabolically Activated Alkylating Agents	361
a.	Nitrosoureas	361
b.	Triazene Antitumor Drugs	363
c.	Mitomycin C	364
d.	Leinamycin	366
6.3.C	DNA Strand Breakers	368
C.1	Anthracycline Antitumor Antibiotics	369
C.2	Bleomycin	371
C.3	Tirapazamine	377
C.4	Enediynes Antitumor Antibiotics	378
a.	Esperamicins and Calicheamicins	380
b.	Dynemicin A	381
c.	Neocarzinostatin (Zinostatin)	381
C.5	Sequence Specificity for DNA Strand Scission	386
6.4	Epilogue to Receptor-Interactive Agents	386
6.5	General References	386
6.6	Problems	387
6.7	References	389
7	Drug Metabolism	405
7.1	Introduction	406
7.2	Synthesis of Radioactive Compounds	408

7.3	Analytical Methods in Drug Metabolism	411
7.3.A	Isolation	412
7.3.B	Separation	412
7.3.C	Identification	413
7.3.D	Quantification	414
7.4	Pathways for Drug Deactivation and Elimination	415
7.4.A	Introduction	415
7.4.B	Phase I Transformations	418
B.1	Oxidative Reactions	418
a.	Aromatic Hydroxylation	420
b.	Alkene Epoxidation	427
c.	Oxidations of Carbons Adjacent to sp^2 Centers	428
d.	Oxidation at Aliphatic and Alicyclic Carbon Atoms	430
e.	Oxidations of Carbon-Nitrogen Systems	430
f.	Oxidations of Carbon-Oxygen Systems	443
g.	Oxidations of Carbon-Sulfur Systems	444
h.	Other Oxidative Reactions	446
i.	Alcohol and Aldehyde Oxidations	447
B.2	Reductive Reactions	448
a.	Carbonyl Reduction	448
b.	Nitro Reduction	450
c.	Azo Reduction	451
d.	Azido Reduction	452
e.	Tertiary Amine Oxide Reduction	452
f.	Reductive Dehalogenation	453
B.3	Carboxylation Reaction	453
B.4	Hydrolytic Reactions	454
7.4.C	Phase II Transformations: Conjugation Reactions	456
C.1	Introduction	456
C.2	Glucuronic Acid Conjugation	456
C.3	Sulfate Conjugation	460
C.4	Amino Acid Conjugation	462
C.5	Glutathione Conjugation	464
C.6	Water Conjugation	466
C.7	Acetyl Conjugation	466
C.8	Fatty Acid and Cholesterol Conjugation	468
C.9	Methyl Conjugation	469
7.4.D	Hard and Soft Drugs; Antedugs	471
7.5	General References	473
7.6	Problems	475
7.7	References	479
8	Prodrugs and Drug Delivery Systems	497
8.1	Enzyme Activation of Drugs	498
8.1.A	Utility of Prodrugs	498
A.1	Aqueous Solubility	499
A.2	Absorption and Distribution	499
A.3	Site Specificity	499